Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting 2024-11-06 09:08
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024 2024-11-06 08:30
Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country 2024-10-18 10:35
Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting 2024-10-07 13:14
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand 2024-09-23 17:42
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024 2024-09-16 18:00
Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization 2024-08-23 12:32
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia 2024-08-06 08:00
Antennova Announces CD73 Small Molecule Inhibitor Accepted for Mini Oral Presentation at ESMO Congress 2024 2024-08-05 20:00
XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country 2024-07-05 21:18
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea 2024-06-26 16:44
Antengene To Present One Oral and Four Abstracts at ASCO 2024 2024-05-24 08:30
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024 2024-04-25 20:00
Antengene Presents Four Preclinical Posters at AACR 2024 2024-04-06 08:30
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline 2024-03-22 18:00
Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia 2024-03-20 20:30
Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research 2024-03-20 08:30
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms 2024-03-06 08:30
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List 2023-12-14 09:55
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States 2023-12-11 08:30
1 2 3 4 5 8